Fecha de publicación: -- Fuente: Biotechblog Lugar: General Biotechnology Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar
For investors, the biosimilar story has been one of the most reliable value creation engines in healthcareuntil you look at antibody-drug conjugates.
So far, the scorecard is zero...
Source